VIETNAM TO RECEIVE 1 MILLION COVID-19 VACCINE DOSES FROM JAPAN

Highlights – Vietnam to receive 1 million COVID-19 vaccine doses from Japan. Japan will also be donating vaccines to Indonesia, Malaysia, the Philippines and Thailand. Vietnam has been facing a resurgence of infections since April. Japan has secured enough AstraZeneca…

6,396 DOSES OF COVID-19 VACCINE DISCARDED IN KAWASAKI PREFECTURE, JAPAN

Highlights – 6,396 doses of COVID-19 vaccine discarded in Kawasaki Prefecture, Japan. Kawasaki Municipal Government had to discard Pfizer Inc.’s vaccine over freezer malfunction. Pfizer’s vaccines are forbidden to be used after being refrozen once thawed. The manufacturer of the…

Merck's KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

Merck’s KEYTRUDA ® (pembrolizumab) Approved in Japan for three additional first-line indications around RCC and chronic or remote metastatic head and neck cancer

KENILWORTH, N.J.-(BUSINESS WIRE)- Merck, branded as MSD outside the United States and Canada, today announced that for the following additional uses in Japan, KEYTRUDA, Merck’s anti-PD-1 medication, received new approvals from the Japan Pharmaceutical and Medical Devices Agency for advanced…

Japan Clinical Research Software Market

Japan Clinical Research Software Market 2019-2025 | Oracle Corporation (US), Medidata Solutions, PAREXEL International Corporation. (US), Bioclinica. (US), Bio-Optronics, Inc. (US), and IBM (US)

Pharmaceutical firms use clinical test management systems to manage clinical trials as a part of their pharmaceutical and biotechnology analysis activities. Medical analysis institutes and research centers managed by hospitals can also use clinical test management code. These systems facilitate…

Multi-targeting partnership agreement between BioLite Japan and American BriVision

An exclusive, global study and multi-targeting partnership and licensing agreement with BioLite Japan have been announced today by the American (Holding) Corporation BriVision (OTCQB: ABV C), which is the clinical phase Biopharmaceutical Company developing Therapy Solutions for Oncology / Hematology,…